logo
Plus   Neg
Share
Email

Roche's Tecentriq Gets 2 EU Approvals To Treat Adults With NSCLC, ES-SCLC

Swiss drug major Roche Group (RHHBY) announced Friday two approvals from European Commission for Tecentriq (atezolizumab) to treat adults with non-squamous non-small cell lung cancer or NSCLC, the most common form of advanced lung cancer, and extensive-stage small cell lung cancer or ES-SCLC, respectively.

In a statement, the company announced that the European Commission or EU has approved and granted marketing authorisation for Tecentriq in combination with chemotherapy (carboplatin and Abraxane), for the initial treatment of adults with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.

This approval is based on results from the Phase III IMpower130 study, which demonstrated that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone in the intention-to-treat wild-type or ITT-WT population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone.

Separately, EU approved Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer or ES-SCLC. Roche noted that this combination is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of ES-SCLC. The combination significantly improved overall survival and progression-free survival for the first time in over 20 years.

This approval is based on results from the Phase III IMpower133 study, which showed that Tecentriq in combination with chemotherapy helped people live significantly longer compared with chemotherapy alone in the intention-to-treat or ITT population. The Tecentriq-based combination also significantly reduced the risk of disease worsening or death compared with chemotherapy alone.

At present, Roche has nine Phase III lung cancer studies underway evaluating Tecentriq alone or in combination with other medicines across different types of lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's has launched its first new seasonal McFlurry flavor in seven years for the holiday season - the Snickerdoodle McFlurry. The holiday treat combines McDonald's creamy vanilla soft serve with crumbles of sweet cinnamon. This is the first new seasonal McFlurry flavour since 2012. The new McFlurry will first be available exclusively on McDelivery with Uber Eats from November 11 to 17. Boeing is hoping to resume deliveries of the 737 MAX aircraft to airline customers in December, when the Federal Aviation Administration is expected to issue an Airworthiness Directive rescinding the grounding order following certification, according to a progress report issued by the aircraft maker. The MAX is also expected to return to commercial service in January 2020. Shares of Deutsche Post DHL Group were gaining around 5 percent in the morning trading in Germany after the package delivery and supply chain management company reported Tuesday significantly higher profit in its third quarter. Looking ahead, the company anticipates a traditionally strong holiday season in the fourth quarter. The company also confirmed its annual earnings outlook.
Follow RTT
>